Kulkarni Abhijeet D, Vanjari Yogesh H, Sancheti Karan H, Belgamwar Veena S, Surana Sanjay J, Pardeshi Chandrakantsing V
a Industrial Pharmacy Laboratory, Department of Pharmaceutics , R. C. Patel Institute of Pharmaceutical Education and Research , Shirpur , Maharashtra , India .
b Department of Pharmaceutical Sciences , R.T.M. Nagpur University , Nagpur , Maharashtra , India , and.
J Drug Target. 2015;23(9):775-88. doi: 10.3109/1061186X.2015.1020809. Epub 2015 Mar 11.
Nose to brain delivery of neurotherapeutics have been tried by several researchers to explore the virtues of this route viz. circumvention of BBB, avoidance of hepatic metabolism, practicality, safety, ease of administration and non-invasiveness. Nanoparticle (NP) therapeutics is an emerging modality for the treatment of Parkinson's disease (PD) as it offers targeted delivery and enhances the therapeutic efficacy and/or bioavailability of neurotherapeutics. This review presents a concise incursion into the nanomedicines suitable for PD therapy delivered via naso-brain transport. Clinical signs of PD, its pathophysiology, specific genetic determinants, diagnosis and therapy involved have been hashed out. Properties of brain-targeting NPs, transport efficacy and various nanocarriers developed so far also been furnished. In our opinion, nanotechnology-enabled naso-brain drug delivery is an excellent means of delivering neurotherapeutics and is a promising avenue for researchers to develop new formulations for the effective management of PD.
几位研究人员尝试了神经治疗药物的鼻脑给药，以探索这种给药途径的优点，即绕过血脑屏障、避免肝脏代谢、实用性、安全性、给药便利性和非侵入性。纳米颗粒（NP）疗法是治疗帕金森病（PD）的一种新兴方式，因为它提供靶向递送并提高神经治疗药物的治疗效果和/或生物利用度。本综述简要介绍了适用于通过鼻脑转运进行PD治疗的纳米药物。PD的临床症状、其病理生理学、特定的遗传决定因素、所涉及的诊断和治疗都已进行了详细讨论。还提供了脑靶向纳米颗粒的特性、转运效率以及迄今为止开发的各种纳米载体。我们认为，纳米技术实现的鼻脑给药是递送神经治疗药物的一种极佳手段，并且是研究人员开发有效管理PD的新制剂的一个有前景的途径。
